MediWound Ltd. (MDWD)
Automate Your Wheel Strategy on MDWD
With Tiblio's Option Bot, you can configure your own wheel strategy including MDWD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MDWD
- Rev/Share 1.874
- Book/Share 2.887
- PB 7.5062
- Debt/Equity 0.2091
- CurrentRatio 1.9654
- ROIC -0.414
- MktCap 234202859.0
- FreeCF/Share -1.7878
- PFCF -12.1399
- PE -7.7369
- Debt/Assets 0.0886
- DivYield 0
- ROE -1.1356
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MDWD | Oppenheimer | -- | Outperform | -- | $34 | June 2, 2025 |
| Initiation | MDWD | Alliance Global Partners | -- | Buy | -- | $25 | May 2, 2025 |
| Initiation | MDWD | Craig Hallum | -- | Buy | -- | $39 | Feb. 28, 2025 |
News
MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Neutral
MediWound Ltd. (NASDAQ:MDWD ) Q1 2025 Earnings Conference Call May 21, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Ofer Gonen - CEO Hani Luxenburg - CFO Barry Wolfenson - EVP of Strategy and Corporate Development Conference Call Participants Chase Knickerbocker - Craig-Hallum RK - H.C.
Read More
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Negative
MediWound (MDWD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.39 per share a year ago.
Read More
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Presentations at WHS and SAWC to highlight EscharEx's mechanism of action, preclinical advantages over SANTYL ® , and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study in VLUs and support the planned DFU trial strategy YAVNE, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will present 10 scientific abstracts—including both oral and poster presentations—at two of the world's premier wound care conferences: the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2025, …
Read More
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Negative
MediWound (MDWD) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.19 per share a year ago.
Read More
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Findings in Burns Journal confirm NexoBrid's superiority over standard of care in pediatric patients with deep thermal burns NexoBrid is approved for pediatric use in the U.S., E.U. and Japan YAVNE, Israel, Feb. 25, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd.
Read More
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will present a corporate overview at the upcoming 45th Annual TD Cowen Health Care Conference, taking place in Boston, MA on Wednesday, March 5, 2025, at 11:50 AM ET.
Read More
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase III trial to assess the efficacy and safety of EscharEx ® for debridement and facilitation of active wound closure
Read More
About MediWound Ltd. (MDWD)
- IPO Date 2014-03-20
- Website https://www.mediwound.com
- Industry Biotechnology
- CEO Mr. Ofer Gonen B.Sc.
- Employees 111